Evidence map›Paper›PMID 27377889›Full record

ArticleVirchows Archiv : an international journal of pathology2016

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

Jelle Wesseling, Corrado Tinterri, Anna Sapino, Fabrizio Zanconati, Martijn Lutke-Holzik, Bichlien Nguyen, Kenneth B Deck, Patrizia Querzoli, Tiziana Perin, Carmela Giardina and 9 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. A predictor of response in HER2+ breast cancer-at last!Journal of the National Cancer Institute · 2023
    Article
  3. Article
  4. Article
  5. Exosomes: A Promising Avenue for the Diagnosis of Breast Cancer.Technology in cancer research & treatment · 2019
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 6 countries.

Jelle WesselingDepartment of Pathology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. j.wesseling@nki.nl.
Corrado TinterriBreast Surgery, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy.
Anna SapinoDepartment of Medical Sciences, Università di Torino, Torino, Italy.
Fabrizio ZanconatiAnatomic Pathology Unit, Università di Trieste, Trieste, Italy.
Martijn Lutke-HolzikDepartment of Surgery, Medisch Spectrum Twente, Enschede and the Saxenburgh Group, Hardenberg, The Netherlands.
Bichlien NguyenDepartment of Medicine, Todd Cancer Institute, Long Beach Memorial Medical Center, Long Beach, CA, USA.
Kenneth B DeckMemorial Care Breast Center, Saddleback Memorial Medical Center, Laguna Hills, CA, USA.
Patrizia QuerzoliSection of Anatomic Pathology, Department of Experimental and Diagnostic Medicine, Università di Ferrara, Ferrara, Italy.
Tiziana PerinDivision of Pathology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
Carmela GiardinaDepartment of Pathological Anatomy, Università degli Studi di Bari, Bari, Italy.
Gerhard SeitzInstitute of Pathology, Klinikum Bamberg, Bamberg, Germany.
Jean-Marc GuinebretièreDepartment of Pathology, Institut Curie, Hôpital René-Huguenin, Saint-Cloud, France.
Julie BaroneComprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA, USA.
Laura DekkerAgendia, Amsterdam, The Netherlands.
Femke de SnooAgendia, Amsterdam, The Netherlands.
Lisette Stork-SlootsAgendia, Amsterdam, The Netherlands.
Paul RoepmanAgendia, Amsterdam, The Netherlands.
Toru WatanabeDepartment of Medicine, Hamamatsu Oncology Center, Shizuoka, Japan.
Pino CusumanoGynecology Oncology Unit, Centre Hospitalier Chrétien, Liège, Belgium.
Agendia (Netherlands) · NLCentre Hospitalier Chrétien · BECentro di Riferimento Oncologico · ITInstitut Curie · FRIRCCS Humanitas Research Hospital · ITLong Beach Memorial Medical Center · USMedisch Spectrum Twente · NLSaddleback Memorial Medical Center · USSharp Memorial Hospital · USSozialstiftung Bamberg · DEThe Netherlands Cancer Institute · NLUniversity of Bari Aldo Moro · ITUniversity of Ferrara · ITUniversity of Trieste · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To compare results from messenger RNA (mRNA)-based TargetPrint testing with those from immunohistochemistry (IHC) and in situ hybridization (ISH) conducted according to local standard procedures at hospitals worldwide. Tumor samples were prospectively obtained from 806 patients at 22 hospitals. The mRNA level of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was assessed by TargetPrint quantitative gene expression readouts. IHC/ISH assessments were performed according to local standards at the participating hospitals. TargetPrint readout showed a high concordance with IHC/ISH of 95 % (kappa 0.81) for ER, 81 % (kappa 0.56) for PR, and 94 % (kappa 0.76) for HER2. The positive/negative agreement between TargetPrint and IHC for ER, PR, and HER2 was 96 %/87 %, 84 %/74 %, and 74 %/98 %, respectively. The concordance rate in IHC/ISH results between hospitals varied: 88-100 % for ER (kappa 0.50-1.00); 50-100 % for PR (kappa 0.20-1.00); and 90-100 % for HER2 (kappa 0.59-1.00). mRNA readout of ER, PR, and HER2 status by TargetPrint was largely comparable to local IHC/ISH analysis. However, there was substantial discordance in IHC/ISH results between different hospitals. When results are discordant, the use of TargetPrint would improve the reliability of hormone receptor and HER2 results by prompting retesting in a reference laboratory.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedReceptors, EstrogenReceptors, ProgesteroneReproducibility of ResultsYoung AdultBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerERHer-2IHC/FishmRNAPgR

Identifiers

PMID27377889
OpenAlexW2469094544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.